Resources
About Us
Home Report
Store
Pharmaceutical Contract Development and Manufacturing Market
Pharmaceutical Contract Development & Manufacturing Market Size, Share, Forecast, & Trends Analysis by Service (Manufacturing [API, FDF {Parenteral, Injectable, Tablet, Capsule, Oral Liquid, Biologics}], Drug Development) End User - Global Forecast to 2031
Report ID:MRHC - 104477 Pages: 250 Aug-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe Pharmaceutical Contract Development and Manufacturing Market was valued at $146.14 billion in 2023. This market is expected to reach $261.57 billion by 2031 from an estimated $158.27 billion in 2024, at a CAGR of 7.4% during the forecast period of 2024-2031.
Pharmaceutical Contract Development and Manufacturing Market Size & Forecast
The growth of this market can be attributed to various factors, such as complex manufacturing requirements of the pharmaceutical industry, manufacturers growing inclination towards the use of cutting-edge technologies, increasing investments in pharmaceutical R&D, patent expiration, and rising demand for generic medicines and biologics. Furthermore, growing demand for cell therapies, gene therapies, and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer growth opportunities.
Pharmaceutical Contract Development and Manufacturing Market Growth Drivers
Increasing Investments in Pharmaceutical R&D
Pharmaceutical companies are allocating significant resources for R&D purposes. This funding is mainly driven by the rising prevalence of chronic diseases due to the growing geriatric population, complexities in clinical trials, and higher failure of drugs in early-phase studies. The increasing funding for R&D purposes is leading to accelerated drug discovery and manufacturing, thereby driving the need for contract manufacturing and development organizations. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), pharmaceutical R&D expenditure is expected to reach USD 213 billion by 2026 from USD 189 billion in 2022. Additionally, governments around the world are ramping up their investments in pharmaceutical and biopharmaceutical research. Various national governments have also launched initiatives to enhance pharmaceutical R&D.
For instance, in March 2023, the Canadian government allocated USD 59 million to the Canadian Critical Drug Initiative to advance drug research and commercialization. Such initiatives are anticipated to drive higher demand for pharmaceutical CDMOs to support efficient manufacturing processes.
Click here to: Get Free Sample Pages of this Report
Complex Manufacturing Requirements of the Pharmaceutical Industry
The pharmaceutical industry is driven mainly by scientific advancements and discoveries in conjunction with clinical and toxicological expertise. In addition to the complex nature of the pharmaceutical manufacturing process, multiple countries offer distinct legal safeguards for exclusive medications and production techniques, commonly referred to as intellectual property rights. Extensive government rules are in place in many countries that impact the development and approval of medications intended for commercial sale. To protect the integrity of drug manufacturing processes and the efficacy, safety, and quality of pharmaceutical goods, these countries have stringent regulations for good manufacturing practices. Due to these difficulties, pharmaceutical companies are now developing and producing medicines and biologics in collaboration with contract manufacturing and development firms.
Pharmaceutical Contract Development and Manufacturing Market Trends
Integration of Process Automation
Process automation involves utilizing software and technologies to streamline business processes and functions, ensuring a consistent workflow and achieving specific tasks. In Contract Development and Manufacturing Organizations (CDMOs), process automation is essential for managing, controlling, and optimizing manufacturing activities. This automation leverages sensors, software, and programmable logic controllers (PLCs) to enhance operations. By integrating these technologies, organizations can centralize and analyze data from sensors, monitor production lines in real time, and improve quality. During the manufacturing process, automated systems look for inconsistencies. If any are found, production is halted to protect workers and preserve product quality.
Additionally, process automation helps eliminate bottlenecks, boost efficiency, and reduce time and costs. These benefits are driving the industry's growing adoption of process automation technology.
Capacity Expansion and Deals to Acquire New Facilities
Capacity expansion is a strategic move of an organization that involves decisions like increasing production capabilities, investment in new units, and adoption or implementation of new technology and equipment. The increase in the number of acquisitions, collaborations, and mergers among CDMOs is a response to some of the major challenges the pharmaceutical industry faces in the development process of drugs, such as the growing number of expiring patents, increasing R&D costs, and increasing prevalence of chronic diseases. Some of the recent strategic developments are as follows:
- In January 2024, WuXi STA (China) opened two new peptide manufacturing plants in China: one in Changzhou and another at their new site in Taixing. This expansion has increased the company’s manufacturing capacity.
- In December 2023, AGC Inc. (Japan) expanded a biopharmaceutical CDMO capability at AGC Yokohama Technical Center in Yokohama, Japan.
Pharmaceutical Contract Development and Manufacturing Market Opportunities
Growing Demand for Cell and Gene Therapies and Personalized Medicines
Next-generation medicines, such as cell and gene therapy, provide significant opportunities for growth in the CDMO market. Cell therapies can benefit patients with neurological disorders, cancer, autoimmune diseases, infectious diseases, urinary tract issues, and compromised immune systems. The need for CDMOs is rising as the number of gene therapy approvals is steadily rising.
The U.S. FDA reports that as of March 2024, 36 gene treatments had received FDA approval, compared to 34 in 2023. A significant barrier to the growth of the cell and gene therapy market is a lack of manufacturing capacity, so large companies outsource the development of their cell or gene therapy processes, creating profitable opportunities for the expansion of the pharmaceutical contract development and manufacturing market.
Pharmaceutical Contract Development and Manufacturing Market Analysis: Key Findings
By Type: In 2024, the Pharmaceutical Manufacturing Services Segment to Dominate the Pharmaceutical Contract Development and Manufacturing Market
Based on type, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2024, the pharmaceutical manufacturing services segment is expected to account for the largest share of 75.6% of the pharmaceutical contract development and manufacturing market. The complex requirements of the manufacturing process, in addition to the high cost associated with drug manufacturing, are increasing the outsourcing of manufacturing services. Small and medium-sized pharmaceutical companies need more manufacturing infrastructure and require technical expertise. Small and medium-sized pharmaceutical companies can lower production costs and uphold medical quality standards by outsourcing to CDMOs. Pharmaceutical firms can focus on their core capabilities by using CDMOs to streamline their manufacturing process, from manufacture to secondary packaging.
However, the biologics manufacturing services segment is estimated to register the highest CAGR of 11.1% during the forecast period. Biologics are becoming progressively more in demand due to their advantages, which include high activity and specificity, few side effects, and the capacity to target particular molecules. The need for manufacturing biologics is growing as these are used in treating infectious, autoimmune, and cardiovascular diseases, and different types of cancers.
The U.S. Food and Drug Administration (FDA) reports that over the last five years, the approval of biologics has increased and now makes up over 25% of all drug approvals; in 2022, 15 biologics were approved out of a total of medicines, up from 13 in 2020. Moreover, the intricacy involved in producing biologics is leading to a rise in outsourcing to CDMOs. CDMO successfully handles issues including scaling up, potential for contamination, and stringent analytical testing. Therefore, it is anticipated that the growth of biologics manufacturing services will be aided by an increase in the percentage of approved biologics, an increase in the complexity of production, and government funding in biologics R&D.
By End User: In 2024, the Large Pharmaceutical Companies Segment to Dominate the Pharmaceutical Contract Development and Manufacturing Market
Based on end user, the pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2024, the large pharmaceutical companies segment is expected to account for the largest share of 42.3% of the pharmaceutical contract development and manufacturing market. The primary drivers accounting for the largest market share of this segment are the increasing demand for modern technology and the emphasis on expanding worldwide in business. Since CDMOs have facilities spread across multiple regions, they are a major source of manufacturing support for large pharmaceutical businesses looking to expand geographically. Due to the increasing complexity of drug research and the rising expenses of building and maintaining those facilities, large biotech and pharmaceutical companies are finding it increasingly necessary to rely on outside contract manufacturers for help running their intricate operations.
Geographical Analysis
In 2024, North America to Dominate the Market
In 2024, North America is expected to account for the largest share of 44.3% of the pharmaceutical contract development and manufacturing market. This region’s large market share is attributed to factors such as the presence of large pharmaceutical and biotechnology manufacturers, biopharmaceutical R&D funding, and rising demand for cell and gene therapies. The region's biopharmaceutical production facilities have grown as a result of the growing demand for biopharmaceuticals and supportive activities for their adoption. Drug shortages are an important concern for consumers in the United States. Drug shortages can be caused by a variety of factors, including delays, discontinuations, and issues with manufacturing and quality.
The U.S. FDA reports that in 2023 there were 98 medicine shortages as opposed to 79 in 2021. Many pharmaceutical companies in the United States are depending on CDMOs to prevent medicine shortages.
Moreover, Asia-Pacific is poised to register the highest CAGR of 8.8% during the forecast period. The region's rapid growth can be attributed to increased awareness of overall health and treatment availability, improved healthcare infrastructure, a growing geriatric population, low-cost manufacturing advantages, rising pharmaceutical R&D expenditure, increased government funding for drug development and research, and rising healthcare spending in the region. The governments of this region are focusing on improving healthcare infrastructure in order to improve patient safety.
In 2022–2023, the Government of India approved 13 foreign direct investment (FDI) proposals, which led to USD 281,400 in foreign investment in the pharmaceutical sector for brownfield projects. These government initiatives and other factors are expected to drive growth in pharmaceutical CDMOs in the Asia-Pacific region.
Pharmaceutical Contract Development and Manufacturing Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years. The key players operating in the pharmaceutical contract development and manufacturing market are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).
Pharmaceutical Contract Development and Manufacturing Market Overview: Latest Developments from Key Industry Players
- In July 2024, Siegfried Holdings AG Holding (Switzerland) acquired Curia Global Inc.'s CDMO location in Wisconsin (U.S.) to enhance drug substance capabilities.
- In June 2024, Vetter Pharma (Germany) expanded manufacturing sites in the US and Germany. These facilities are expected to be completely operational in 2030. The development is expected to boost the company's footprint in the US market.
- In March 2024, Lonza Group (Switzerland) agreed to pay USD 1.2 billion to Genentech, Inc. (US), a subsidiary of F. Hoffmann-La Roche AG, for the biologics production plant in California. The acquisition is planned to boost the company's large-scale biologics manufacturing capabilities for mammalian medicines and broaden its regional presence in the U.S.
- In September 2023, Samsung Biologics (South Korea) signed an agreement with Bristol Myers Squibb (U.S.) for commercial production of antibody cancer drug substances.
Pharmaceutical Contract Development and Manufacturing Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
~250 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
7.4% |
|
Estimated Market Size (Value) |
$261.57 billion by 2031 |
|
Segments Covered |
By Type
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Denmark, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa. |
|
Key Companies |
are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FULJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FULJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.). |
Key questions answered in the pharmaceutical contract development and manufacturing market report:
The pharmaceutical contract development and manufacturing market report covers the qualitative and quantitative analysis of the market. This report involves analyzing various segments of pharmaceutical contract development and manufacturing, such as type, end user, and regional and country-level studies. The report also provides insights on factors impacting market growth, regulatory analysis, factor analysis, and Porter’s five forces analysis.
The pharmaceutical contract development and manufacturing market is projected to reach $261.57 billion by 2031 at a CAGR of 7.4% from 2024 to 2031.
Among all the types studied in this report, in 2024, the pharmaceutical manufacturing services segment is expected to account for the largest share, 75.6%, of the pharmaceutical contract development and manufacturing market. The largest share of the segment is attributed to increasing investment in R&D, the need to reduce manufacturing costs, and the increase in demand for high-volume drug manufacturing.
The growth of this market can be attributed to various factors, such as complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination towards the use of innovative technologies, increasing investments in pharmaceutical R&D, patent expiration, and rising demand for generic medicines and biologics are expected to drive the growth of the market. Furthermore, growing demand for cell therapies, gene therapies, and personalized medicines growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer growth opportunities.
The key players operating in the pharmaceutical contract development and manufacturing market are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).
Among all the geographies studied in this report, Asia-Pacific is expected to register the highest CAGR of 8.8% during the forecast period. This region’s growth is attributed to its growing geriatric population, rising awareness of overall health and treatment availability, growing healthcare spending, improving healthcare infrastructure, low-cost manufacturing advantages, rising pharmaceutical R&D expenditure, and increasing government funding for drug development and research.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Complex Manufacturing Requirements of the Pharmaceutical Industry
4.2.2. Manufacturers' Growing Inclination Towards the Use of Cutting-Edge Technologies
4.2.3. Increasing Investments in Pharmaceutical R&D
4.2.4. Patent Expiration
4.2.5. Rising Demand for Generic Medicines and Biologics
4.3. Restraints
4.3.1. Disruption in Supply Chain
4.3.2. Stringent Government Regulations
4.4. Opportunities
4.4.1. Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
4.4.2. Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
4.5. Challenges
4.5.1. Intellectual Property Risks
4.5.2. Shortage of Skilled Professionals
4.6. Factor Analysis
4.7. Trends
4.7.1. Integration of Process Automation
4.7.2. Digital Automation
4.7.3. Capacity Expansion and Deals to Acquire New Facilities
4.8. Regulatory Analysis
4.9. Value Chain Analysis
4.10. Porter’s Five Force Analysis
5. Pharmaceutical Contract Development and Manufacturing Market Assessment—by Type
5.1. Overview
5.2. Pharmaceutical Manufacturing Services
5.2.1. Active Pharmaceutical Ingredient (API) Manufacturing Services
5.2.2. Finished Dosage Forms (FDF) Manufacturing Services
5.2.2.1. Parenteral/Injectable Manufacturing Services
5.2.2.2. Tablet Manufacturing Services
5.2.2.3. Capsule Manufacturing Services
5.2.2.4. Oral Liquid Manufacturing Services
5.2.2.5. Other Formulations
5.3. Drug Development Services
5.4. Biologics Manufacturing Services
5.4.1. Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
5.4.2. Finished Dosage Form Manufacturing (FDF) Services
6. Pharmaceutical Contract Development and Manufacturing Market Assessment—by End Users
6.1. Overview
6.2. Large Pharmaceutical Companies
6.3. Small & Mid-Size Pharmaceutical Companies
6.4. Generic Pharmaceutical Companies
7. Pharmaceutical Contract Development and Manufacturing Market Assessment—by Geography
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Switzerland
7.3.7. Netherlands
7.3.8. Denmark
7.3.9. Rest of Europe (RoE)
7.4. Asia-Pacific
7.4.1. Japan
7.4.2. China
7.4.3. India
7.4.4. South Korea
7.4.5. Australia
7.4.6. Singapore
7.4.7. Rest of Asia-Pacific (RoAPAC)
7.5. Latin America
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Rest of Latin America (RoLATAM)
7.6. Middle East & Africa
8. Competition Analysis
8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
8.4.1. Industry Leaders
8.4.2. Market Differentiators
8.4.3. Vanguards
8.4.4. Emerging Companies
8.5. Market Share Analysis/Market Ranking, by Key Players (2023)
9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
9.1. Lonza Group Ltd.
9.2. Catalent, Inc.
9.3. Patheon (Subsidiary of Thermo Fisher Scientific Inc.)
9.4. Recipharm AB
9.5. C.H. Boehringer Sohn AG & CO. KG.
9.6. Aurobindo Pharma, Ltd.
9.7. Jubilant Pharmova Limited
9.8. Fareva SA
9.9. Vetter Pharma International GmbH
9.10. Aenova Group
9.11. WuXi Biologics Co., Ltd.
9.12. Piramal Enterprises Limited.
9.13. Almac Group
9.14. Fabbrica Italiana Sintetici S.p.A. (F.I.S.)
9.15. Samsung Biologics Co., Ltd.
9.16. Cambrex Corporation
9.17. Siegfried Holdings AG
9.18. FUJIFILM Diosynth Biotechnologies (Subsidiary of FUJIFILM Holdings Corporation)
9.19. Curia Global, Inc.
(Note: SWOT analysis of the top 5 companies will be provided.)
10. Appendix
10.1. Available Customization
10.2. Related Reports
List of Tables
Table 1 Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 2 Global Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 3 Global Pharmaceutical Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 4 Global Active Pharmaceutical Ingredient (API) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 5 Global Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 6 Global Finished Dosage Forms (FDF) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 7 Global Parenteral/Injectable Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 8 Global Tablet Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 9 Global Capsule Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 10 Global Oral Liquid Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 11 Global Pharmaceutical Manufacturing Services Market for Other Formulations, by Country/Region, 2022-2031 (USD Million)
Table 12 Global Drug Development Services Market, by Country/Region, 2022-2031 (USD Million)
Table 13 Global Biologics Manufacturing Services, by Type, 2022-2031 (USD Million)
Table 14 Global Biologics Manufacturing Services, by Country/Region, 2022-2031 (USD Million)
Table 15 Global Active Pharmaceutical Manufacturing Services (API) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 16 Global Finished Dosage Form Manufacturing (FDF) Services Market, by Country/Region, 2022-2031 (USD Million)
Table 17 Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 18 Global Pharmaceutical Contract Development and Manufacturing Market for Large Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
Table 19 Global Pharmaceutical Contract Development and Manufacturing Market for Small & Mid-Size Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
Table 20 Global Pharmaceutical Contract Development and Manufacturing Market for Generic Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
Table 21 Global Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024–2031 (USD Million)
Table 22 North America: Pharmaceutical Contract Development and Manufacturing Market, by Country, 2024-2031 (USD Million)
Table 23 North America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 24 North America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 25 North America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 26 North America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 27 North America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 28 U.S.: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 29 U.S.: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 30 U.S.: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 31 U.S.: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 32 U.S.: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 33 Canada: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 34 Canada: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 35 Canada: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 36 Canada: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 37 Canada: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 38 Europe: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
Table 39 Europe: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 40 Europe: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 41 Europe: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 42 Europe: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 43 Europe: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 44 Germany: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 45 Germany: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 46 Germany: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 47 Germany: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 48 Germany: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 49 France: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024- 2031 (USD Million)
Table 50 France: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 51 France: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 52 France: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 53 France: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 54 U.K.: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 55 U.K.: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 56 U.K.: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 57 U.K.: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 58 U.K.: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 59 Italy: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 60 Italy: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 61 Italy: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 62 Italy: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 63 Italy: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 64 Spain: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 65 Spain: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 66 Spain: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 67 Spain: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 68 Spain: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 69 Switzerland: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 70 Switzerland: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 71 Switzerland: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 72 Switzerland: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 73 Switzerland: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 74 Netherlands: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 75 Netherlands: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 76 Netherlands: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 77 Netherlands: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 78 Netherlands: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 79 Denmark: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 80 Denmark: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 81 Denmark: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 82 Denmark: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 83 Denmark: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 84 Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 85 Rest of Europe: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 86 Rest of Europe: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 87 Rest of Europe: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 88 Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 89 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
Table 90 Asia- Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 91 Asia-Pacific: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 92 Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 93 Asia-Pacific: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 94 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 95 China: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 96 China: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 97 China: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 98 China: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 99 China: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 100 India: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 101 India: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 102 India: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 103 India: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 104 India: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 105 Japan: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 106 Japan: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 107 Japan: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 108 Japan: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 109 Japan: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 110 South Korea: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 111 South Korea: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 112 South Korea: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 113 South Korea: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 114 South Korea: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 115 Australia: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 116 Australia: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 117 Australia: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 118 Australia: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 119 Australia: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 120 Singapore: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 121 Singapore: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 122 Singapore: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 123 Singapore: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 124 Singapore: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 125 Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 126 Rest of Asia-Pacific: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 127 Rest of Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 128 Rest of Asia-Pacific: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 129 Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 130 Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
Table 131 Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 132 Latin America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 133 Latin America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 134 Latin America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 135 Latin America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 136 Brazil: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 137 Brazil: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 138 Brazil: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 139 Brazil: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 140 Brazil: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 141 Mexico: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 142 Mexico: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 143 Mexico: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 144 Mexico: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 145 Mexico: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 146 Rest of Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 147 Rest of Latin America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 148 Rest of Latin America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 149 Rest of Latin America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 150 Rest of Latin America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 151 Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
Table 152 Middle East & Africa: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 153 Middle East & Africa: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 154 Middle East & Africa: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
Table 155 Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
Table 156 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2031 (USD Million)
Figure 8 Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2031 (USD Million)
Figure 9 Global Pharmaceutical Contract Development and Manufacturing Market, by Geography
Figure 10 Impact Analysis of Market Dynamics
Figure 11 Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2031 (USD Million)
Figure 12 Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2031 (USD Million)
Figure 13 Global Pharmaceutical Contract Development and Manufacturing Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 14 North America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 15 Europe: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 16 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 17 Latin America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 18 Key Growth Strategies Adopted by Leading Players, 2021—2024
Figure 19 Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Type
Figure 20 Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Geography
Figure 21 Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Dashboard
Figure 22 Global Pharmaceutical Contract Development and Manufacturing Market: Market Share Analysis/Market Ranking, by Key Players (2023)
Figure 23 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 24 C.H. Boehringer Sohn AG & CO. KG.: Financial Snapshot (2023)
Figure 25 Catalent, Inc.: Financial Snapshot (2023)
Figure 26 FUJIFILM Diosynth Biotechnology: Financial Snapshot (2023)
Figure 27 Samsung Biologics: Financial Snapshot (2023)
Figure 28 Siegfried Holding AG: Financial Snapshot (2023)
Figure 29 Aenova Group: Financial Snapshot (2023)
Figure 30 WuXi Biologics: Financial Snapshot (2023)
Figure 31 Vetter Pharma International GmbH: Financial Snapshot (2023)
Figure 32 Lonza Group Ltd.: Financial Snapshot (2023)
Figure 33 Recipharm AB: Financial Snapshot (2023)
Figure 34 Aurobindo Pharma ,Ltd: Financial Snapshot (2023)
Figure 35 Jubilant Pharmova Limited: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
